Trial Profile
A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of MLN8237 in Japanese Subjects with Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Oct 2017
Price :
$35
*
At a glance
- Drugs Alisertib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda
- 02 Jun 2016 New trial record